Woburn, Massachusetts -- Biotechnology company BioVex has raised $40 million in its fifth round of institutional venture capital financing.
BioVex is developing a new class of Biologics for the treatment of cancer and prevention of infectious disease.
The financing round was led by Forbion Capital Partners and included investments by Harris & Harris Group, New Science Ventures, Triathlon Medical Ventures, Innoven Partners and Scottish Equity Partners. The company said the funds would be used to commence its Phase III study for its lead cancer product.
|